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Family-history collection is one of the key strategies for
identification of individuals at increased risk of certain
types of cancer. Primary-care physicians are the gate-
keepers of this information, which is used to decide who
might require earlier, more frequent, or more sensitive
cancer screening. The first time you visit a new doctor
and fill out all of the required paperwork, a family history
questionnaire is usually one component. But how often
are these histories updated, and how might these updates
influence screening recommendations? Ziogas et al. use
retrospective and prospective data from the Cancer
Genetics Network to explore this issue. This population-
based registry included self-reported family history infor-
mation on breast, colorectal, and prostate cancer for up
to 10 years of follow-up. They found that between the
ages of 30 and 50 years there are increases in the clinically
relevant family history of colorectal and breast cancer and
that these increases could change cancer screening recom-
mendations, leading them to suggest that the family
history of cancer be updated every 5 to 10 years. Family
trees grow and change with time; these changes must be
noted to maximize the usefulness of family histories in
guiding cancer screening recommendations.
Ziogas et al. (2011). JAMA 306, 172–178.
Nonmuscle-Myosin Mutations Linked to Kidney
Disease
Despite the discovery of mutations that cause the progres-
sive kidney disease focal segmental glomerulosclerosis in
more than 20 genes, the underlying cause of this disorder
is unknown in about half of patients. The typical approach
to therapy, which uses glucocorticoids, is also ineffective in
a significant fraction of patients; at least half progress to
end-stage renal disease. Mele et al. recently found muta-
tions in a new disease gene, encoding the nonmuscle
myosin Myo1E; this discovery gives insight into the path-
ogenesis of focal segmental glomerulosclerosis and could
lead to improvements in treatment. Myo1E localizes to po-
docytes, a specialized type of epithelial cell that is a critical
component of the glomerulus, which is the filtering unit in
the kidney. In cells expressing wild-type but not mutant
Myo1E, the protein is enriched in the characteristic foot
processes of the podocyte and promotes podocytemotility,
presumably through stabilization of the podocyte cyto-
skeleton. Cyclosporine is a second-line treatment for focal1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Americsegmental glomerulosclerosis, although it is not effective
in all patients. It was originally thought that it alleviated
symptoms because of its immunosuppressive effects, but
other data suggest that it acts through stabilization of the
podocyte cytoskeleton. The fact that three of four patients
with MYO1E mutations were responsive to cyclosporine
therapy supports this idea and further emphasizes the
importance of podocyte structure inmaintaining the filtra-
tion barrier in the glomerulus.
Mele et al. (2011). NEJM. Published online July 13, 2011.
10.1056/NEJMoa1101273.
Getting Clearance to Avoid Alzheimer Disease
The strongest known genetic risk factor for typical, late-
onset Alzheimer disease (AD) is the apolipoprotein E
epsilon 4 allele (APOE ε4). ApoE4 influences the accumula-
tion of the amyloid-b (Ab) peptide, which is presumed to
trigger the pathogenic cascade leading to the dementia
that is the hallmark of this disease. As recently shown by
Castellano et al., even in cognitively normal individuals,
the level of Ab in the cerebrospinal fluid of individuals
with the APOE ε4/ε4 genotype is lower than it is in individ-
uals with other genotypes, and these levels reflect
increased accumulation of Ab in the brain. This is sup-
ported by imaging data indicating that the frequency of
healthy individuals with evidence of amyloid plaques is
increased in the group with an APOE ε4 allele. One could
imagine that apoE4 alters Ab accumulation either by influ-
encing its production or its clearance, but clear data had
been lacking to distinguish the mechanism until Castel-
lano et al. measured these parameters in mice expressing
human apoE. They used in vivo microdialysis to demon-
strate that mice expressing apoE4 are less able to clear Ab
from brain interstitial fluid than those expressing apoE2
or E3, whereas the generation of Ab was not influenced
by APOE genotype. Although it is unknown how apoE
influences Ab clearance, further understanding of this
process could illuminate a pathway that could be targeted
by therapies aimed at AD.
Castellano et al. (2011). Sci. Transl. Med. 3, 89ra57.
Experiments Identify an Xist-ing Bridge
A crucial player in the inactivation of one X chromosome
in each female mammalian cell is the long noncoding RNA
Xist. This RNA is preferentially expressed fromwhat will be
the inactive X chromosome and eventually coats theta, GA 30322, USA
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length of the chromosome, leading to gene repression and
chromatin modification. A key aspect of this system that
has been unclear is how Xist identifies and binds to the
inactive X chromosome. Contrary to previous ideas, Jeon
and Lee have recently shown that Xist is not inherently
cis-acting. In fact, Xist RNA can diffuse through the cell
and is stable when not bound to chromatin. Instead, the
binding of Xist RNA to the X inactivation center is medi-
ated by the protein YY1, which binds only to the inactive
X chromosome. YY1 forms a bridge between Xist RNA and
its DNA in the X inactivation center, thereby tethering Xist
RNA to its chromosome of origin. In their model, Xist RNA
cannot bind to the active X chromosome because the YY1
binding sites are blocked in an as-yet-unidentified fashion.
This work defines a nucleation center for X chromosome
inactivation; further work is needed to understand how
Xist binding spreads in cis along the chromosome.
Jeon and Lee (2011). Cell 146, 119–133.
Molecular Analysis of 22q13.3 Deletions
Individuals with chromosome 22q13.3 deletions, other-
wise known as Phelan-McDermid syndrome, tend to have
global developmental delays, neonatal hypotonia, and200 The American Journal of Human Genetics 89, 199–200, August 1severe speech issues. The long-term natural history of this
syndrome has been less clear because of a dearth of reports
of affected adults. Bonaglia et al. recently collected a group
of 44 individuals with Phelan-McDermid syndrome,
including three in their forties. Although the sample size
is small, the syndrome does seem to be associated with
progressive clinical decline. The authors also attempted to
clone and characterize the deletion breakpoints in the
sample in order to use 22q13.3 deletions as amodel to study
terminal chromosome deletions. A range of repair mecha-
nisms was implicated in these patients as a group, but the
data from one patient indicate that separate repair events
can actually occur in different cells in the early embryo;
these repair events result in mosaicism. This patient was
mosaic for three cell lines with breakpoints ranging over
100 kb. Although not exceedingly common, this syndrome
is of interest to a wider group of researchers because
haploinsufficiency for SHANK3, a gene implicated in
autism, is believed to be critical for many of the deficits
associated with Phelan-McDermid syndrome. The group
of patients analyzed in this study includes five who have
microdeletions involving only SHANK3.
Bonaglia et al. (2011). PLOS Genet. 7, e1002173.This Month in Our Sister JournalsReduced Penetrance of Null Mutations in COL3A1
Vascular-type Ehlers-Danlos syndrome (EDS), otherwise
known as EDS type IV, is caused by dominant mutations
in the collagen gene COL3A1. Although null mutations
make up the minority of known cases, data from other
collagenopathies suggest that haploinsufficiency could be
associated with a different clinical course than that seen
with missense or exon-skipping mutations. Data from
a recent study by Leistritz et al. suggest that this is, in
fact, the case. Of their collection of more than 500 families
with COL3A1 mutations, 19 had premature termination
codons, which were associated with nonsense-mediated
decay in all patients tested. Using data from the index
patients and 26 relatives who also tested positive for
a COL3A1 mutation and comparing them to previous
data on the natural history of EDS type IV, the authors
found evidence that null mutations are less likely to be
penetrant. When complications do occur, they tend to
happen at an older age than in individuals with missense
or exon-skipping mutations, and they are limited to
vascular events. The frequency of null mutations in their
collection of EDS type IV patients also suggests underascer-
tainment of these individuals. Perhaps contributing to this
is the fact that minor clinical features of EDS type IV are
absent in at least half of individuals with a null mutation,
and these features are often used as a testing indicator. The
authors propose relaxing the testing threshold for COL3A1mutations to include families with later-onset arterial
aneurysm to determine whether more null mutations
might be found in this group.
Leistritz et al. (2011). Genet. Med. Published online June 1,
2011. 10.1097/GIM0b013e3182180c89.
AnApproach to the Use of High-Throughput Sequence
Data in Population Genetics
The distribution of allele frequencies in a sample of individ-
uals, or the site-frequency spectrum, is a useful parameter
in population genetics. Although high-throughput se-
quencing generates reams of data for calculation of the
site-frequency spectrum, it is not without problems. For
one, samplingvariationcanmeanthatoneallele at ahetero-
zygous site is underrepresented—or even absent—from the
sequence data. On the other hand, sequence errors can be
misinterpreted as polymorphisms. This is a particular chal-
lenge in species with low nucleotide diversity, such as hu-
mans, where the frequency of errors is high relative to the
frequency of true changes. Keightley and Halligan have
developed a maximum-likelihood model to estimate site-
frequency spectra from high-throughput sequence data.
Their method is robust to nonrandom error and suitable
for low-coverage data, such as the Yoruban sample from
the 1000 Genomes Project that they use as an illustration.
Keightley and Halligan. (2011). Genetics. Published online
May 19, 2011. 10.1534/genetics.111.128355.2, 2011
